Raymond James Initiates Coverage On This Stock With Bullish Pitch On Gene Therapies Raymond James initiated coverage on Rocket Pharmaceuticals Inc (NASDAQ: RCKT ) with an Outperform rating with a $22 price target based on the positive view of RP-L102 and RP-L201 gene therapy programs and LAD-I. Rocket could file for approval in both programs as early as next year, with potential pre-BLA meetings in 2022. Despite the known risks, Raymond James thinks experts favor LVV-based gene therapies in rare pediatric diseases. Related: Rocket Pharma''s … Full story available on Benzinga.com